Inflammatory cytokines: from discoveries to therapies in IBD

Microbial network disturbances in relapsing refractory Crohn’s disease

(2019) Bahtiyar Yilmaz et al.   NATURE MEDICINE

IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease

(2019) Lyssia Belarif et al.   JOURNAL OF CLINICAL INVESTIGATION

Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease

(2018) A. Barré et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease

(2018) Heike Schmitt et al.   GUT

Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study

(2018) Bruce E Sands et al.   Journal of Crohns & Colitis

A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage

(2018) Vu L. Ngo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair

(2018) Loris R. Lopetuso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases

(2018) Jason Reinglas et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease

(2018) Paul Rutgeerts et al.   GASTROENTEROLOGY

Inhibiting Interleukin 36 Receptor Signaling Reduces Fibrosis in Mice with Chronic Intestinal Inflammation

(2018) Kristina Scheibe et al.   GASTROENTEROLOGY

Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms

(2018) Julia Pazmandi et al.   IMMUNOLOGICAL REVIEWS

Mast cells are essential intermediaries in regulating IL-33/ST2 signaling for an immune network favorable to mucosal healing in experimentally inflamed colons

(2018) Zhigang He et al.   Cell Death & Disease

Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn’s Disease in Treatment-Naive Pediatric Patients

(2017) Michael J. Rosen et al.   GASTROENTEROLOGY

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease: Results from Celest

(2017) William J. Sandborn et al.   GASTROENTEROLOGY

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

(2017) Silvio Danese et al.   GUT

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

(2017) Julian Panés et al.   GUT

IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis

(2017) Junfeng Zhu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

(2017) Séverine Vermeire et al.   LANCET

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

(2017) Siew C Ng et al.   LANCET

Crohn's disease

(2017) Joana Torres et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Ulcerative colitis

(2017) Ryan Ungaro et al.   LANCET

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease

(2017) Nathaniel R West et al.   NATURE MEDICINE

Current and emerging therapeutic targets for IBD

(2017) Markus F. Neurath   Nature Reviews Gastroenterology & Hepatology

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

(2017) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

An increase in serum tumour necrosis factor-α during anti-tumour necrosis factor-α therapy for Crohn's disease – A paradox or a predictive index?

(2016) Piotr Eder et al.   DIGESTIVE AND LIVER DISEASE

Interleukin 1β Mediates Intestinal Inflammation in Mice and Patients With Interleukin 10 Receptor Deficiency

(2016) Dror S. Shouval et al.   GASTROENTEROLOGY

Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial

(2016) William J. Sandborn et al.   GASTROENTEROLOGY

IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo

(2016) Kristina Scheibe et al.   GUT

IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation

(2016) S E Russell et al.   Mucosal Immunology

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases

(2016) Ulrike Billmeier et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

(2015) Julián Panés et al.   BMC GASTROENTEROLOGY

Interleukin-34 sustains inflammatory pathways in the gut

(2015) Eleonora Franzè et al.   CLINICAL SCIENCE

Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study

(2015) Walter Reinisch et al.   GUT

Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage

(2015) Oscar Medina-Contreras et al.   JOURNAL OF IMMUNOLOGY

Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3+ Treg cell function in the intestine

(2015) O J Harrison et al.   Mucosal Immunology

A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

(2014) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel Disease

(2014) Holm H. Uhlig et al.   GASTROENTEROLOGY

Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study

(2014) Silvio Danese et al.   GUT

IL-9 and its receptor are predominantly involved in the pathogenesis of UC

(2014) Nancy Nalleweg et al.   GUT

Pleiotropic functions of TNF-  in the regulation of the intestinal epithelial response to inflammation

(2014) M. Leppkes et al.   INTERNATIONAL IMMUNOLOGY

IL-33 Is an Unconventional Alarmin That Stimulates IL-2 Secretion by Dendritic Cells To Selectively Expand IL-33R/ST2+Regulatory T Cells

(2014) Benjamin M. Matta et al.   JOURNAL OF IMMUNOLOGY

IL-13 Orchestrates Resolution of Chronic Intestinal Inflammation via Phosphorylation of Glycogen Synthase Kinase-3 

(2014) S. Fichtner-Feigl et al.   JOURNAL OF IMMUNOLOGY

Epithelial expression of interleukin-37b in inflammatory bowel disease

(2013) H. Imaeda et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Selective JAK/STAT3 signalling regulates transcription of colony stimulating factor-2 and -3 in Concanavalin-A-activated mesenchymal stromal cells

(2013) Alain Zgheib et al.   CYTOKINE

Absence of a role for interleukin-13 in inflammatory bowel disease

(2013) Paolo Biancheri et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Intraepithelial Type 1 Innate Lymphoid Cells Are a Unique Subset of IL-12- and IL-15-Responsive IFN-γ-Producing Cells

(2013) Anja Fuchs et al.   IMMUNITY

Incidence, Paris Classification, and Follow-up in a Nationwide Incident Cohort of Pediatric Patients With Inflammatory Bowel Disease

(2013) Katalin E. Müller et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues

(2013) Jochem H Bernink et al.   NATURE IMMUNOLOGY

Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease

(2013) Mehmet Coskun et al.   PHARMACOLOGICAL RESEARCH

Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s Disease

(2013) Francesca Zorzi et al.   PLoS One

The Age of Gene Discovery in Very Early Onset Inflammatory Bowel Disease

(2012) Aleixo M. Muise et al.   GASTROENTEROLOGY

Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis

(2012) Clémentine Perrier et al.   INFLAMMATORY BOWEL DISEASES

IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+Th17 cells

(2012) Margherita Coccia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Unknown

(2012) Lihua Duan et al.   MOLECULAR MEDICINE

Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease

(2012) Luke Jostins et al.   NATURE

IL-12 family cytokines: immunological playmakers

(2012) Dario A A Vignali et al.   NATURE IMMUNOLOGY

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

(2012) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors

(2011) Claude Haan et al.   CHEMISTRY & BIOLOGY

Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated Inflammation

(2011) Ashutosh Chaudhry et al.   IMMUNITY

IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease

(2011) Alessandra Geremia et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis

(2011) Claudia Günther et al.   NATURE

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47

(2011) Carl A Anderson et al.   NATURE GENETICS

Interleukin 37 expression protects mice from colitis

(2011) E. N. McNamee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor necrosis factor α blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells

(2010) Hak-Ling Ma et al.   ARTHRITIS AND RHEUMATISM

Interleukin-23 Drives Intestinal Inflammation through Direct Activity on T Cells

(2010) Philip P. Ahern et al.   IMMUNITY

The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis

(2010) Md. Hasan Zaki et al.   IMMUNITY

Control of Intestinal Homeostasis, Colitis, and Colitis-Associated Colorectal Cancer by the Inflammatory Caspases

(2010) Jeremy Dupaul-Chicoine et al.   IMMUNITY

Diverse Targets of the Transcription Factor STAT3 Contribute to T Cell Pathogenicity and Homeostasis

(2010) Lydia Durant et al.   IMMUNITY

Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases

(2010) Massimiliano Sarra et al.   INFLAMMATORY BOWEL DISEASES

Long-term complications, extraintestinal manifestations, and mortality in adult Crohnʼs disease in population-based cohorts

(2010) Laurent Peyrin-Biroulet et al.   INFLAMMATORY BOWEL DISEASES

Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends

(2010) Eric I. Benchimol et al.   INFLAMMATORY BOWEL DISEASES

Infant colitis—it's in the genes

(2010) Erik-Oliver Glocker et al.   LANCET

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis

(2010) Luca Pastorelli et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Up-regulation of signal transducer and activator of transcription-3 is associated with aggravation of ulcerative colitis

(2010) Fujun LI et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Fontolizumab in moderate to severe Crohnʼs disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study

(2009) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

Signaling Molecules: The Pathogenic Role of the IL-6/STAT-3 Trans Signaling Pathway in Intestinal Inflammation and in Colonic Cancer

(2008) R. Atreya et al.   CURRENT DRUG TARGETS

A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease

(2008) William J. Sandborn et al.   GASTROENTEROLOGY

IL-21 comes of age as a regulator of effector T cells in the gut

(2008) M C Fantini et al.   Mucosal Immunology